Details
| Stereochemistry | RACEMIC |
| Molecular Formula | 2C15H22N2O2.H2O4S |
| Molecular Weight | 622.773 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.CC(C)NCC(O)COC1=CC=CC2=C1C=C(C)N2.CC(C)NCC(O)COC3=CC=CC4=C3C=C(C)N4
InChI
InChIKey=PNYFXKOIFMZVQC-UHFFFAOYSA-N
InChI=1S/2C15H22N2O2.H2O4S/c2*1-10(2)16-8-12(18)9-19-15-6-4-5-14-13(15)7-11(3)17-14;1-5(2,3)4/h2*4-7,10,12,16-18H,8-9H2,1-3H3;(H2,1,2,3,4)
| Molecular Formula | H2O4S |
| Molecular Weight | 98.078 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C15H22N2O2 |
| Molecular Weight | 262.3474 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Mepindolol is a selective beta1-adrenoreceptor blocker with intrinsic sympathetic activity. Treatment with mepindolol dose not significantly affect the lipid levels - the total cholesterol in plasma was decreased by mepindolol but HDL-cholesterol increased. During beta-receptor blockade with mepindolol-sulfate angina was compensated, the unfavourable hemodynamic effects seen during placebo did not occur. No signs of congestive heart failure were found during mepindolol-sulfate-therapy. Mepindolol-sulfate showed a pronounced blood-pressure lowering effect.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Role of chemical structure in stereoselective recognition of beta-blockers by cyclodextrins in capillary zone electrophoresis. | 2008-04-24 |
|
| Transdermal delivery of beta-blockers. | 2006-05 |
|
| Role of chemical structure in stereoselective recognition of beta-blockers and H1-antihistamines by human serum transferrin in capillary zone electrophoresis. | 2006-04 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:30:17 GMT 2025
by
admin
on
Mon Mar 31 18:30:17 GMT 2025
|
| Record UNII |
63523X4FBA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6917859
Created by
admin on Mon Mar 31 18:30:17 GMT 2025 , Edited by admin on Mon Mar 31 18:30:17 GMT 2025
|
PRIMARY | |||
|
SUB03157MIG
Created by
admin on Mon Mar 31 18:30:17 GMT 2025 , Edited by admin on Mon Mar 31 18:30:17 GMT 2025
|
PRIMARY | |||
|
236904
Created by
admin on Mon Mar 31 18:30:17 GMT 2025 , Edited by admin on Mon Mar 31 18:30:17 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000086421
Created by
admin on Mon Mar 31 18:30:17 GMT 2025 , Edited by admin on Mon Mar 31 18:30:17 GMT 2025
|
PRIMARY | |||
|
56396-94-2
Created by
admin on Mon Mar 31 18:30:17 GMT 2025 , Edited by admin on Mon Mar 31 18:30:17 GMT 2025
|
PRIMARY | |||
|
260-153-6
Created by
admin on Mon Mar 31 18:30:17 GMT 2025 , Edited by admin on Mon Mar 31 18:30:17 GMT 2025
|
PRIMARY | |||
|
63523X4FBA
Created by
admin on Mon Mar 31 18:30:17 GMT 2025 , Edited by admin on Mon Mar 31 18:30:17 GMT 2025
|
PRIMARY | |||
|
m7193
Created by
admin on Mon Mar 31 18:30:17 GMT 2025 , Edited by admin on Mon Mar 31 18:30:17 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |